Johnson & Johnson (JNJ) Shares Sold by First PREMIER Bank
First PREMIER Bank cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,791 shares of the company’s stock after selling 284 shares during the quarter. Johnson & Johnson comprises approximately 4.3% of First PREMIER Bank’s investment portfolio, making the stock its 3rd biggest position. First PREMIER Bank’s holdings in Johnson & Johnson were worth $5,661,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. State Street Corp increased its stake in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. Korea Investment CORP grew its holdings in shares of Johnson & Johnson by 38.9% during the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after purchasing an additional 596,134 shares during the period. Bank of Nova Scotia grew its holdings in shares of Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares during the period. Oppenheimer Asset Management Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $65,598,000. Finally, CIBC World Markets Inc. grew its holdings in shares of Johnson & Johnson by 111.8% during the 1st quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after purchasing an additional 500,662 shares during the period. 66.00% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/johnson-johnson-jnj-shares-sold-by-first-premier-bank.html.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Shares of Johnson & Johnson (NYSE JNJ) traded up 0.11% during trading on Friday, reaching $134.33. The company had a trading volume of 5,307,273 shares. The firm has a 50-day moving average of $132.51 and a 200 day moving average of $129.09. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The firm has a market capitalization of $360.54 billion, a price-to-earnings ratio of 22.73 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
JNJ has been the subject of a number of research analyst reports. UBS AG reiterated a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. BMO Capital Markets reiterated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a report on Friday, September 1st. Finally, BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a report on Sunday, May 21st. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $134.60.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.